Characteristics | Â | PFS | OS | ||||||
---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | ||
Age (years) | Continuous variable | 0.98 (0.95 − 1.01) | 0.1148 |  |  | 0.98 (0.94 − 1.01) | 0.1984 |  |  |
Sex | Female/male | 0.94 (0.58 − 1.54) | 0.8097 |  |  | 0.73 (0.42 − 1.26) | 0.2574 |  |  |
ECOG PS | 1 − 3/0 | 1.44 (0.89 − 2.33) | 0.1391 |  |  | 1.46 (0.85 − 2.51) | 0.1747 |  |  |
Smoking history | Never-smoker/smoker | 1.00 (0.61 − 1.63) | 0.9876 |  |  | 0.74 (0.43 − 1.30) | 0.2985 |  |  |
Immune checkpoint inhibitor | Nivolumab/pembrolizumab | 2.10 (1.33 − 3.34) | 0.0016 | 2.07 (1.30 − 3.28) | 0.0021 | 2.31 (1.38 − 3.87) | 0.0015 |  |  |
Line of treatment | Second or higher/first | 1.68 (1.01 − 2.78) | 0.0440 |  |  | 1.74 (0.97 − 3.12) | 0.0613 |  |  |
Histology | Sq/non-Sq | 1.62 (0.98 − 2.67) | 0.0590 | 1.55 (0.94 − 2.57) | 0.0849 | 1.57 (0.92 − 2.67) | 0.0954 | 1.80 (1.05 − 3.09) | 0.0337 |
Clinical stage | Advanced/recurrent | 1.25 (0.72 − 2.16) | 0.4332 |  |  | 0.90 (0.48 − 1.68) | 0.7433 |  |  |
Body mass index (kg/m2) | < 22/≥22 | 0.90 (0.58 − 1.42) | 0.6637 |  |  | 0.84 (0.51 − 1.38) | 0.4834 |  |  |
Mutation status (EGFR or ALK) | Othersa /wild-type | 1.02 (0.54 − 1.93) | 0.9529 |  |  | 0.85 (0.41 − 1.73) | 0.6498 |  |  |
PD-L1 tumor proportion score | Othersb/≥50% | 1.90 (1.17 − 3.10) | 0.0100 |  |  | 2.36 (1.33 − 4.18) | 0.0033 | 2.29 (1.28 − 4.08) | 0.0052 |
Statin therapy | Yes/no | 0.76 (0.48 − 1.19) | 0.2277 |  |  | 0.60 (0.36 − 0.99) | 0.0456 | 0.61 (0.36 − 1.02) | 0.0585 |